Cos (e.g., Cos-7, Etc.) Patents (Class 435/365)
Expressing recombinant lymphokine, interferon, hormone, growth factor or morphogen (Class 435/365.1)
-
Publication number: 20140162331Abstract: Disclosed are an amphipathic peptide-lipase conjugate with enhanced lipase activity, a polynucleotide coding for the conjugate, an expression vector carrying the polynucleotide, a transformant anchoring the expression vector therein, a method for preparing the conjugate, a lipolysis method using the conjugate, and a method for producing biodiesel using the lipase.Type: ApplicationFiled: August 10, 2012Publication date: June 12, 2014Inventors: Sun-Chang Kim, Bong Hyun Sung, Kyung Seok Yang, Jun Hyoung Lee, Ki Jung Lim, Myung Keun Park
-
Patent number: 8748578Abstract: The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.Type: GrantFiled: September 8, 2011Date of Patent: June 10, 2014Assignee: Max-Planck-Gesellschaft zur Foerderrung der Wissenschaften e.V.Inventors: Ernst Bamberg, Christian Bamann, Sonja Kleinlogel, Phillip Wood, Robert E. Dempski
-
Publication number: 20140154281Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides.Type: ApplicationFiled: August 9, 2012Publication date: June 5, 2014Applicant: Onco Therapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura
-
Publication number: 20140155326Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 21, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
-
Publication number: 20140154283Abstract: Described herein is the identification and of a potent West Nile virus (WNV) CD4 positive T cell epitope and its use for increasing the immunogenicity of heterologous flavivirus vaccines, such as dengue virus type 2 (DENV-2) DNA and virus-like particle (VLP) vaccines. Also described are methods for the identification of potent T cell epitopes to enhance immunogenicity of multivalent vaccines.Type: ApplicationFiled: July 11, 2012Publication date: June 5, 2014Applicants: Department of health and Human ServicesInventors: Gwong-Jen J. Chang, Holly R. Hughes
-
Publication number: 20140155325Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 20, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
-
Publication number: 20140147453Abstract: The present invention relates to a fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhFas-1 domain which is the fourth fas-1 domain of ?ig-h3 lacking H1 and H2 regions; b) a MMP (Matrix metalloproteinase) substrate; and c) a peptide comprising RGD motif and an use thereof for preventing and treating inflammatory disease. The fusion peptide of the present invention inhibits expension of rheumatoid arthritis by adhesion and migration of sinoviocytes and may be used for preventing or treating inflammatory disease by inhibiting infiltration of immune cells.Type: ApplicationFiled: May 31, 2013Publication date: May 29, 2014Applicant: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Young Mo Kang, In San Kim, Jin Hee Kang, Keum Hee Sa
-
Publication number: 20140147458Abstract: The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient.Type: ApplicationFiled: February 24, 2012Publication date: May 29, 2014Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Geun Hee Kim, Shi Nae Kwon, Chan Hee Lee, Yeop Yoon
-
Publication number: 20140148355Abstract: The present invention relates to polypeptides that bind to H3K4 methylated chromatin, and in particular to the use of reagents comprising such polypeptides for epigenetic/epigenomic analysis.Type: ApplicationFiled: March 28, 2012Publication date: May 29, 2014Applicant: UNIVERSITY OF OSLOInventors: Reidunn B. Aalen, Tage Thorstensen, Rein Aasland, Verena Hoppmann
-
Publication number: 20140140978Abstract: The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.Type: ApplicationFiled: June 15, 2012Publication date: May 22, 2014Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE PARIS SUD-PARIS XI, INRA (Institut National de la Recherche Agronomique)Inventors: David Machover, Pascal Bonnarme
-
Publication number: 20140134722Abstract: The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided.Type: ApplicationFiled: June 17, 2010Publication date: May 15, 2014Inventor: Alexey Ryazanov
-
Publication number: 20140134740Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.Type: ApplicationFiled: October 28, 2013Publication date: May 15, 2014Applicant: Sangamo BioSciences, Inc.Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
-
Publication number: 20140134723Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.Type: ApplicationFiled: October 28, 2013Publication date: May 15, 2014Applicant: Sangamo BioSciences, Inc.Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
-
Patent number: 8722618Abstract: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.Type: GrantFiled: April 27, 2012Date of Patent: May 13, 2014Assignee: Janssen Biotech, Inc.Inventors: Steven Jacobs, Karyn O'Neil, Michael Baumann, Gaby Sennhauser
-
Publication number: 20140127246Abstract: It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Bira Arya, Vladimir L. Larionov
-
Publication number: 20140120133Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.Type: ApplicationFiled: October 22, 2013Publication date: May 1, 2014Applicants: MERIAL LIMITED, UNIVERSITY OF PRETORIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jules Maarten Minke, Jean Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
-
Publication number: 20140120154Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: ApplicationFiled: October 26, 2012Publication date: May 1, 2014Inventor: Claresa Levetan
-
Publication number: 20140120091Abstract: The present invention provides improved fusion proteins for therapy of autoimmune and cardiovascular disease.Type: ApplicationFiled: October 31, 2013Publication date: May 1, 2014Inventors: Jeffrey A LEDBETTER, Martha LEDBETTER, Vince MONTES, Alan CHAIT, Sonya SLATER
-
Publication number: 20140120085Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.Type: ApplicationFiled: September 25, 2013Publication date: May 1, 2014Applicant: BioNTech AGInventors: Özlem TÜRECI, Ugur SAHIN, Sandra SCHNEIDER, Gerd HELFTENBEIN, Volker SCHLÜTER, Dirk USENER, Philippe THIEL, Michael KOSLOWSKI
-
Publication number: 20140107020Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Publication number: 20140101785Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.Type: ApplicationFiled: March 13, 2013Publication date: April 10, 2014Applicant: HOWARD HUGHES MEDICAL INSTITUTEInventors: Loren Looger, Karel Svoboda, Douglas Kim, Rex Kerr
-
Publication number: 20140099280Abstract: The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.Type: ApplicationFiled: February 24, 2012Publication date: April 10, 2014Applicant: Cenre National De La Recherche ScientifiqueInventors: Jean-Philippe Girard, Corinne Cayrol-Girard, Emma Lefraancais
-
Publication number: 20140094404Abstract: The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin-derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells.Type: ApplicationFiled: January 13, 2012Publication date: April 3, 2014Inventors: Antonio Pedro Villaverde Corrales, Esther Vázquez Gómez, Neus Ferrer Miralles, Ugutz Unzueta Elorza, Ramón Mangues Bafalluy, Maria Virtudes Céspedes Navarro, Isolda Casanova Rigat
-
Publication number: 20140087426Abstract: This application provides transcription activator-like effector nucleases (TALENs), polynucleotide sequences encoding the TALENs, expression cassettes for producing TALENs to target cleavage of nucleic acids, and methods of producing and using the TALENs.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: The Chinese University of Hong KongInventors: Yun LIU, Christopher H.K. Cheng
-
Publication number: 20140090111Abstract: The invention provides fusion proteins comprising at least two fluorescent proteins, with the fluorescent proteins emitting different wavelengths of light from one another, at least one plant hormone binding domain that changes three-dimensional conformation upon specifically binding to a plant hormone, and two linker peptides, with the first linker linking the first fluorescent protein to the N-terminus of the plant hormone binding domain and the second linker linking the second fluorescent protein to the C-terminus of the plant hormone binding domain. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.Type: ApplicationFiled: September 5, 2013Publication date: March 27, 2014Applicant: Carnegie Institution of WashingtonInventors: Wolf B. Frommer, Alexander M. Jones
-
Publication number: 20140079643Abstract: The present invention relates to a novel protein skeletal module which increases the binding affinity or binding specificity of active polypeptides. More particularly, the present invention relates to a protein skeletal module comprising polypeptides consisting of the 1st to 19th amino acids of the amino acid sequence expressed in sequence number 1; polypeptides comprising active polypeptides; and polypeptides consisting of the 29th to 86th amino acids of the amino acid sequence expressed in sequence number 1. The present invention also relates to a method for preparing the protein skeletal module. The protein skeletal module of the present invention increases the binding affinity or binding specificity of active polypeptides embedded therein, and therefore is effective in diagnosing and treating diseases.Type: ApplicationFiled: October 18, 2013Publication date: March 20, 2014Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Kiweon CHA, In-Seop So, Soyoun Kim, Byung-Heon Lee, In San Kim
-
Publication number: 20140072561Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.Type: ApplicationFiled: September 17, 2013Publication date: March 13, 2014Applicant: CSL BEHRING GMBHInventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
-
Publication number: 20140073572Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.Type: ApplicationFiled: October 1, 2013Publication date: March 13, 2014Applicants: MUSC Foundation for Research Development, The Regents of the University of Colorado, a Body CorporateInventors: Gary GILKESON, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
-
Publication number: 20140073019Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: ApplicationFiled: March 7, 2012Publication date: March 13, 2014Applicant: PURAC BIOCHEM B.V.Inventors: Nick Johannes Petrus Werckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Publication number: 20140058790Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.Type: ApplicationFiled: November 30, 2011Publication date: February 27, 2014Applicant: AmideBio LLCInventors: Michael H.B. Stowell, Mikhail Plam
-
Publication number: 20140057335Abstract: The present invention is directed generally to cell culture media useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells in the presence of said media. Cells containing introduced materials can be further cultured in the media. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention thus provides efficient and high throughput methods to transform/transfect culture and cells avoiding the need for multiple manipulations and transfers of cells during transfection and expression studies.Type: ApplicationFiled: August 15, 2013Publication date: February 27, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Valentina C. CICCARONE, Dale Gruber, Shelly Bennett
-
Publication number: 20140050693Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicant: TECHNISCHE UNIVERSITAT MUNCHENInventors: Ame Skerra, Ina Theobald, Martin Schlapschy
-
Publication number: 20140051630Abstract: A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught.Type: ApplicationFiled: January 28, 2013Publication date: February 20, 2014Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: Michael RUDNICKI, Johnathan SMID
-
Publication number: 20140050732Abstract: The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.Type: ApplicationFiled: March 15, 2013Publication date: February 20, 2014Inventors: Fabrice Bureau, Hughes Wallemacq, Philippe Boutet, Pierre Lekeux, Laurence Fievez, Julien Pujol
-
Publication number: 20140044699Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: September 13, 2013Publication date: February 13, 2014Applicants: ALTIF LABORATORIES INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Hitoshi SAKURABA, Youichi TAJIMA, Ikuo KAWASHIMA, Seiichi AIKAWA, Fumiko AIKAWA
-
Publication number: 20140044773Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: May 7, 2013Publication date: February 13, 2014Inventor: Portola Pharmaceuticals, Inc.
-
Patent number: 8647870Abstract: A biological photoreceptor, which is a directly light-controlled ion channel, including (i) an apoprotein and (ii) a light-sensitive polyene covalently bound to the apoprotein, the polyene interacting with the apoprotein and functioning as a direct light-sensitive gate.Type: GrantFiled: April 23, 2012Date of Patent: February 11, 2014Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Publication number: 20140038234Abstract: A short human genomic nucleotide sequence from the SAR3 region of the human interferon ?2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.Type: ApplicationFiled: March 20, 2012Publication date: February 6, 2014Applicant: National Research Council of CanadaInventor: Yves Durocher
-
Publication number: 20140038908Abstract: The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same.Type: ApplicationFiled: February 28, 2013Publication date: February 6, 2014Applicant: MT. SINAI HOSPITALInventors: Isabella Caniggia, Martin Post, Nima Soleymanlou, Andrea Jurisicova
-
Publication number: 20140038233Abstract: There is provided an expression vector for animal cell having an increased gene expression efficiency, and particularly, an expression vector for animal cells including a MAR element and a SAR element, which are gene expression increasing factors, at a 5? end of a promoter, a 3? end of a transcription termination site, or at both of the 5? end of the promoter and the 3? end of the transcription termination site. The expression vector for animal cells according to the present invention exhibits remarkably increased gene expression efficiency as compared to conventional expression vectors for animal cells, such that protein expression of foreign genes may be significantly increased using this expression vector for animal cells. Particularly, the expression vector for animal cells according to the present invention may be useful in that a high-expression cell line may be secured even without MTX amplification.Type: ApplicationFiled: March 30, 2012Publication date: February 6, 2014Applicant: PANGEN BIOTECH INC.Inventors: Jaeseung Yoon, Kwanghee Baek, Taeho Byun, JeongSoo Park
-
Publication number: 20140017679Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.Type: ApplicationFiled: April 17, 2013Publication date: January 16, 2014Applicant: BioNTech AGInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
-
Publication number: 20140005356Abstract: The present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is in vivo incorporated instead of a tyrosine residue, and a method for producing the same. More specifically, the present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is incorporated instead of a tyrosine residue, and a method for producing the same, and a transformant for producing the recombinant mussel adhesive protein.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Inventors: Hyung Joon CHA, Byeongseon Yang, Yoo Seong Choi, Hyungdon Yun
-
Publication number: 20130344537Abstract: The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies.Type: ApplicationFiled: May 3, 2013Publication date: December 26, 2013Inventor: Chung-Ming HSIEH
-
Patent number: 8603778Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: GrantFiled: July 12, 2012Date of Patent: December 10, 2013Assignee: Janssen Biotech, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Publication number: 20130323187Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.Type: ApplicationFiled: November 26, 2012Publication date: December 5, 2013Applicant: PARTNERSHIP & CORP. TECHNOLOGY TRANSFERInventors: Nicolas Fasel, Amal Kuendig
-
Publication number: 20130323769Abstract: The present invention provides a fusion protein including sarco/endoplasmic reticulum calcium ATPase, a fluorescence donor for FRET, and a fluorescence acceptor, one of the fluorescence donor and the fluorescence acceptor being linked to the N-terminus side of the ATPase, the other of the fluorescence donor and the fluorescence acceptor being inserted between the above one of the fluorescence donor and the fluorescence acceptor and the ATPase or being inserted in an amino acid sequence of the ATPase, the amino acid sequence corresponding to (i) amino acids 1 through 6 in SERCA2a, (ii) amino acids 369 through 380 in the SERCA2a or (iii) amino acids 572 through 583 in the SERCA2a.Type: ApplicationFiled: January 13, 2012Publication date: December 5, 2013Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, RIKENInventors: Katsuhiko Mikoshiba, Toru Matsu-Ura, Kanayo Satoh
-
Patent number: 8597910Abstract: Von Willebrand's Factor (VWF) is produced using an expression vector that includes: 1) a DNA sequence encoding a functional VWF protein; and 2) regulatory DNA capable of effecting expression of that DNA sequence in a host cell transformed with the vector. Restriction fragment length polymorphisms (RFLP's) associated with the VWF gene are identified and used in a probe for determining the source of a VWF gene in a DNA sample. The gene for VWF is localized to the short arm of human chromosome 12 (12p).Type: GrantFiled: July 23, 1990Date of Patent: December 3, 2013Assignee: Children's Medical Center CorporationInventors: David Ginsburg, Stuart H. Orkin, Randal J. Kaufman
-
Publication number: 20130316952Abstract: Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.Type: ApplicationFiled: May 23, 2013Publication date: November 28, 2013Applicant: Janssen Biotech, Inc.Inventor: Janssen Biotech, Inc.
-
Publication number: 20130318640Abstract: The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.Type: ApplicationFiled: December 10, 2012Publication date: November 28, 2013Applicants: Baxter International Inc., Baxter Healthcare SAInventors: Baxter Healthcare SA, Baxter International Inc.
-
Publication number: 20130316959Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: ApplicationFiled: July 10, 2013Publication date: November 28, 2013Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi